TY - JOUR
T1 - Subchronic/chronic toxicity of a mixture of four chlorinated dibenzo-p- dioxins in rats
T2 - I. Design, general observations, hematology, and liver concentrations
AU - Viluksela, Matti
AU - Stahl, Bernhard U.
AU - Birnbaum, Linda S.
AU - Schramm, Karl Werner
AU - Kettrup, Antonius
AU - Rozman, Karl K.
N1 - Funding Information:
We appreciate the skillful technical assistance of Margitta Lebofsky, Cindy Palmer, and Sandra Markham (Department of Pharmacology, Toxicology, and Therapeutics, University of Kansas Medical Center), and Stacey Brooks, Reginald Pierce, and Richard Smith (Laboratory Animal Resources, University of Kansas Medical Center). We thank Drs. Michael J. DeVito and Angelique P. J. M. Van Birgelen for helpful comments on the manuscript. Although the research described in this article has been funded in part by the U. S. States Environmental Protection Agency under assistance agreement CR 820241-01-0 to K.K.R., it has not been subjected to the Agency’s peer and administrative review and, therefore, may not necessarily reflect the views of the Agency, and no official endorsement should be inferred. Support was also obtained from GSF-Forschungszentrum für Umwelt und Gesundheit, Germany, the Academy of Finland, Research Council for Environmental Sciences (Grant 5410/4011/89), and European Commission (Contract ENV4-CT96-0336). Bernhard Stahl was supported by a fellowship of the Deutsche For-schungsgemeinschaft (Sta 300/3-1).
PY - 1998/7
Y1 - 1998/7
N2 - Groups of 20 male and 20 female rats were administered five different doses of a mixture of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), 1,2,3,7,8- pentaCDD (PCDD), 1,2,3,4,7,8-hexaCDD (HxCDD), and 1,2,3,4,6,7,8-heptaCDD (HpCDD). Doses were selected based on relative potency factors derived from acute toxicity data and a previous subchronic study with HpCDD. The mixture was constituted such that each of the congeners contributed one fourth to total toxic equivalency. Total doses were divided into four daily loading doses and six biweekly maintenance doses. The highest total dose for males was 17.5 μg/kg of TCDD, 87.5 μg/kg of PCDD, 350 μg/kg of HxCDD, and 2500 μg/kg of HpCDD. Positive controls were administered PCDD (350 μg/kg) or HxCDD (1400 μg/kg). Females were given 1.5 times lower doses than males. The dosing period was 13 weeks, after which half of the rats were necropsied and the rest provided with an off-dose period of another 13 weeks. Liver concentrations as determined by GC-MS reflected the doses administered. Body weight gain was dose-dependently reduced throughout the study. Mortality rates at the end of the off-dose period were 80 and 60% for the two highest dosages (mixture) in males and 70 and 10% for females. Clinical signs and necropsy findings suggested that the cause of death was related to wasting, hemorrhage, and anemia. Prothrombin times were prolonged and platelet counts were decreased in some rats receiving high doses. This study provides in vivo support for the validity of the assumption of additive toxicity of CDDs as currently used in the toxicity equivalency factor approach to assess the toxicity of mixtures of CDDs.
AB - Groups of 20 male and 20 female rats were administered five different doses of a mixture of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), 1,2,3,7,8- pentaCDD (PCDD), 1,2,3,4,7,8-hexaCDD (HxCDD), and 1,2,3,4,6,7,8-heptaCDD (HpCDD). Doses were selected based on relative potency factors derived from acute toxicity data and a previous subchronic study with HpCDD. The mixture was constituted such that each of the congeners contributed one fourth to total toxic equivalency. Total doses were divided into four daily loading doses and six biweekly maintenance doses. The highest total dose for males was 17.5 μg/kg of TCDD, 87.5 μg/kg of PCDD, 350 μg/kg of HxCDD, and 2500 μg/kg of HpCDD. Positive controls were administered PCDD (350 μg/kg) or HxCDD (1400 μg/kg). Females were given 1.5 times lower doses than males. The dosing period was 13 weeks, after which half of the rats were necropsied and the rest provided with an off-dose period of another 13 weeks. Liver concentrations as determined by GC-MS reflected the doses administered. Body weight gain was dose-dependently reduced throughout the study. Mortality rates at the end of the off-dose period were 80 and 60% for the two highest dosages (mixture) in males and 70 and 10% for females. Clinical signs and necropsy findings suggested that the cause of death was related to wasting, hemorrhage, and anemia. Prothrombin times were prolonged and platelet counts were decreased in some rats receiving high doses. This study provides in vivo support for the validity of the assumption of additive toxicity of CDDs as currently used in the toxicity equivalency factor approach to assess the toxicity of mixtures of CDDs.
UR - https://www.scopus.com/pages/publications/0031721982
U2 - 10.1006/taap.1998.8384
DO - 10.1006/taap.1998.8384
M3 - Article
C2 - 9705887
AN - SCOPUS:0031721982
SN - 0041-008X
VL - 151
SP - 57
EP - 69
JO - Toxicology and Applied Pharmacology
JF - Toxicology and Applied Pharmacology
IS - 1
ER -